Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Melanoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Liposarcoma 1Leiomyosarcoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 4tremelimumab 3Pemetrexed 3durvalumab 2atezolizumab 2Radiotherapy 2Nivolumab 2Mitomycin 2Doxorubicin 2toripalimab 1talazoparib 1rucaparib 1regorafenib 1ranpirnase 1pembrolizumab 1niraparib 1liposomal doxorubicin 1dostarlimab 1cemiplimab 1bemcentinib 1avelumab 1abemaciclib 1Vinorelbine 1Vinblastine 1Thiostrepton 1Surgical Procedures, Operative 1Oxaliplatin 1One-Lung Ventilation 1Neoadjuvant Therapy 1Megestrol Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Mesothelioma, Malignant × cemiplimab × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡